low-level and broad Sox3 expression is initiated in the cephalic ectoderm of otic region at developmental stage (st.) 8. Then, a Sox2 expression is followed in the otic area at st. 9, and these expressions are maintained in the entire otic placode at st. 11 (Uchikawa et al., 2011) . The expression of both Sox2 and Sox3 is regulated by many enhancers that respond to regional and temporal cues (Nishimura et al., 2012; Okamoto, Uchikawa, & Kondoh, 2015; Uchikawa, Ishida, Takemoto, Kamachi, & Kondoh, 2003; , some of which are only activated in specific placodes. Among these, the Otic1 enhancer is uniquely specific to the otic placode and regulates Sox3. Moreover, the enhancer activity of Otic1 prevails across the entire area of the otic placode and its derivatives, the otic pit and otic vesicle.
Therefore, in this study, we investigated how the specificity of the otic placode is determined by analyzing the mechanisms that underlie Otic1 enhancer activation and that confine its activity to the otic placode. Our findings indicated that the Otic1 enhancer is activated by a combination of the TFs Sall4 and Sox8/Sox9 in the otic placode and cephalic neural crest, while additional repression mechanisms involving Zeb TFs and Snail2 confine the enhancer activity to the otic placode. Interestingly, an analogous combination of activation and repression mechanisms operates on the NOP1 enhancer of Sox2, which is bipotent for the nasal and otic placodes (Sugahara et al., 2018; Uchikawa et al., 2003) . These mechanisms that underlie the otic placode-specific enhancer activities presumably play major regulatory roles during the early stages of inner ear development.
| E XPERIMENTAL PROCEDURE S

| Analysis of the Otic1 enhancer using chicken embryo electroporation
Chicken embryos were staged according to Hamburger and Hamilton (1951) , placed in modified New's culture, and electroporated according to the procedure described by Uchikawa (2008) .
Analysis of subfragments of the D3 sequence (Nishimura et al., 2012) and multiplication of these fragments to increase their enhancer activities were performed using the principle outlined by Kondoh and Uchikawa (2008) . The fluorescence intensities resulting from reporter expression were recorded using an SZX12 microscope (Olympus) and DP70 CCD camera (Olympus). The green fluorescence intensities in given tissue areas that represented enhancer strength were compared with red fluorescence from a co-electroporated control vector and analyzed using Image J (Schneider, Rasband, & Eliceiri, 2012) after subtracting the background fluorescence levels.
The data presented in the photopanels shown in this paper were adjusted for background levels using Photoshop (Adobe) to facilitate a fair comparison between fluorescence intensities.
| In situ hybridization
Whole-mount in situ hybridization of chicken embryos for Sox8, Sox9, Sox10, and Sall4 expression was performed according to Uchikawa et al. (2003) . The probe sequences, and data for Sox8, Sox9 and Sall4 will be reported in a separate paper (Sugahara et al., 2018) . The Sox10 cDNA (917-1539 of GenBank ID: AF152356) was used for a probe.
| Chromatin immunoprecipitation-quantitative polymerase chain reaction (ChIP-qPCR) analysis
Cephalic tissues from st. 11-12 embryos were analyzed according to the procedure described in Sugahara et al. (2018) . The primer pair for Otic1 sequence was Otic1_F 5′-TGTCTCTGCTCTGGGAAAGC-3′ and Otic1_R 5′-AAGACAGCAGTGTGGCTTCA-3′. Antibodies used for immunoprecipitation of Sox8-and Sox9-bound chromatins were anti-SOX8 rabbit antibody (NBP1-92425; Novus Biologicals) and anti-Sox9 rabbit antibody (AB5535, CHEMICON [Merck]), respectively.
| Transactivation assay
Luciferase reporters carrying the Otic1 core sequence octamer were co-transfected with varying amounts of effector vectors, as described by Kamachi, Uchikawa, Tanouchi, Sekido, and Kondoh (2001) , in the quail fibroblast cell line QT6 (Moscovici et al., 1977) .
A transactivation assay was then performed using a Dual Luciferase Assay System (Promega).
| Embryonic stem cells carrying the Otic1 reporter system
An Otic1-driven tTA2 expression vector with Tol2 terminal repeats, pT2AL200R175-Otic1-tk-tTA2, was constructed by combining the Tol2 terminal repeats of pT2AL200R175 (Urasaki, Morvan, & Kawakami, 2006) , the herpes simplex virus thymidine kinase promoter unit in enhanced green fluorescent protein (tkEGFP) (Uchikawa et al., 2003) , and the tTA2 coding sequence (Urlinger et al., 2000) . A tetracycline-controlled transactivator (tTA)-dependent expression plasmid with Tol2 terminal repeats, pT2K-BI-EGFP-Puro, was constructed by modifying the pT2K-BI-TRE-EGFP vector (Sato et al., 2007; Watanabe et al., 2007) with insertion of the puromycin-resistance gene. These vectors were transfected with the transposase expression vector pCS-TP (Kawakami et al., 2004) and pCAGGS-mCherry-2A-Puro in R1 mouse embryonic stem cells (ESCs) (Nagy, Rossant, Nagy, Abramow-Newerly, & Roder, 1993) , and stable transfectants were selected with 1 μg/ml puromycin. To obtain the otic placode patches from the ESCs, the cells were allowed to develop in two-step cultures, i.e., aggregation to form embryoid bodies and spreading culture to derive the placodes, under the conditions described by Oshima et al. (2010) , with the exception that Dkk1 was replaced with 1 μmol/L XAV939 in the first step and the Fgf2 concentration was increased to 100 ng/ml in the second step.
| Transient transgenic zebrafish embryos
Zebrafish fertilized eggs were injected with 1 nl of enhancer-carrying tk-nlsVenus transgene DNA (Okuda, Ogura, Kondoh, & Kamachi, 2010) at 25 pg/nl, according to the procedure described in Ogura, Okuda, Kondoh, and Kamachi (2009) but without use of I-SceI.
| RE SULTS
| Delimiting the Otic1 enhancer region
In our previous study of enhancers that regulate the chicken Sox3 gene (Nishimura et al., 2012) , we found that the 5-kb-long D3 genomic fragment located approximately 40 kb downstream of the gene bears an enhancer that is specific to the otic placode and its derivatives ( Figure 1 ). We named this enhancer Otic1 and characterized it in this study. When the otic placode area of a chicken embryo was electroporated at st. 4 with the D3-tkEGFP vector, the Otic1 enhancer started to show its activity at st. 10 in the otic placode, increased its activity at st. 11 when the otic placode began to invaginate, and further increased its activity in the entire area of the otic pit (st. 13) and otic vesicle (st. 15) (Figure 1b) .
To delimit the Otic1 enhancer region within the D3 genomic fragment, we produced a series of subfragments and tested the enhancer activity of each in the otic placode at st. 11 (Figure 2) . To do this, we co-electroporated pCMV-mRFP1 or ptkmCherry D3 fragment 1 to control the electroporation efficiency. The full Otic1 enhancer activity was detected when fragment 1 (1.5 kb) was used, but not when the upstream fragment 2 was used. Therefore, we analyzed various subfragments of fragment 1 (Figure 2b ). We found that fragment 3 (363 bp) and its subdivided fragment 7 (181) showed otic placode-specific enhancer activity. Because fragment 7 was the shortest sequence that showed enhancer activity in the otic placode as a monomer and because this sequence is conserved among avian species (see Figure 7a , below), we concluded that fragment 7 was the Otic1 enhancer sequence. It was noted, however, that the enhancer activities of fragments 3 and 7 were much weaker than that of fragment 1, indicating that some elements outside fragment 3 augment the Otic1 enhancer activity. Enhancer activity of the D3 sequence fragments 1, 3, and 7, as indicated by the expression of EGFP in electroporated embryos, and the absence of enhancer activity in fragment 2. Electroporation was controlled by coelectroporation with pCMV-mRFP1 or ptkmCherry carrying fragment 1. Note that the enhancer activity was significantly reduced with fragments 3 or 7 compared with fragment 1. The bar indicates 500 μm
| Dissecting the regulatory elements of the Otic1 enhancer
To determine the regulatory elements that are involved in generating the Otic1 enhancer activity, we first augmented the enhancer activity via tandem dimerization of the enhancer (Kondoh & Uchikawa, 2008) . The enhancer activity of the Otic1 dimer was significantly higher than that of the monomer, but also generated weak enhancer activity in the cephalic region into which neural crest cells migrate ( Figure 3c , wild type [WT] ). This observation indicated that the Otic1 sequence may carry not only activating elements, but also repressing elements, which shut off the enhancer activity in the non-otic placode region in the monomeric form but have an insufficient repressing effect in the dimeric form. The following deletion and mutational analyses were performed using the dimeric form of the sequences.
Step-wise deletions from the 5′ end of the WT Otic1 sequence were performed (Figure 3a) . Deletion of the 5′ sequences up to 97 bp had no significant effect on the enhancer activity ( Figure 
| TF binding sites in the minimal activating sequence of the Otic1 enhancer
To determine the TF binding sites in the 68-bp minimal activating sequence of the Otic1 enhancer, we introduced 3-to 4-bp consecutive mutations to the sequence, as summarized in Figure 4a , which also provides an indication of the potential binding sites for some TFs. The mutated sequences were dimerized and placed upstream of the tkEGFP vector, and the mutational effects were assessed by the EGFP expression levels (Figure 4b ). Quantitatively assessed EGFP expression levels are summarized in Figure 4c . The spectrum of the mutational effects was almost identical between the otic placode and the cephalic tissue, confirming that the Otic1 enhancer is activated by the same mechanism in these tissues.
| Sall4 and Sox8 act as cooperating partner TFs binding to the Otic1 core sequence
To further characterize the TF-Otic1 interactions, we octamerized partial sequences of the 68 base pairs, which has been shown to boost even very weak enhancer activities borne by particular sequences (Kondoh & Uchikawa, 2008) . Initially, we octamerized two which we hereafter refer to as the "Otic1 core" sequence, was sufficient to generate an enhancer activity that was analogous to the octamer of the 1-44 sequence, presumably providing binding sites for two essential TFs (Figure 5c ). The introduction of mutations 3 or 6 to the core sequence totally inactivated the enhancer activity, confirming the binding of two TFs to respective sites of this sequence.
In the Otic1 core sequence, the mutated sequences 2 and 3 overlap with the Sall4 binding sequence [C/T]AGAGC (Sugahara et al., 2018) , while the mutated sequences 5 and 6 include the Sox factor binding sequence TTTGT. Therefore, since a parallel study on the
NOP1 enhancer of Sox2 identified the combination of Sall4 and SoxE
TFs as the major regulators of enhancer activation (Sugahara et al., 2018) , we investigated the expression patterns of related TFs, the binding of the TFs to the Otic1 enhancer sequence using a ChIPqPCR analysis, and their effects on the enhancer activation using the Otic1 core sequence octamer.
Sall4 was expressed in a wide range of tissues at st. 11 (Figure 5d ).
Among the SoxE genes Sox8, Sox9, and Sox10, the expression patterns of Sox8 and Sox10 closely resemble the pattern of enhancer activity of the Otic1 core octamer, while Sox9 is activated in the otic placode when the Otic1 activity becomes prominent (Figure 5d ).
Consequently, since Sox10 expression in the otic placode is activated by Sox8 (Betancur, Sauka-Spengler, & Bronner, 2011) , we focused our study on Sox8 and Sox9, among SoxE TFs, in the otic placode development.
We then performed ChIP-qPCR analysis of cephalic tissues (anterior to the 4th somites) in st. 11-12 embryos for the binding of Sall4, Sox8 and Sox9 to the Otic1 enhancer sequence, comparing with two control sequences (Sugahara et al., 2018) . As shown in Figure 6b , ChIP using anti-Sall4, Sox8 and Sox9 caused significant enrichment of the Otic1 sequence, confirming binding of these TFs to the Otic1 sequence in vivo.
We also investigated the activity of Sox8 and Sall4 in the activation of the core sequence octamer compared with other related TFs.
The core octamer sequence was inserted upstream of the δ51-lucII reporter (Kamachi & Kondoh, 1993) and co-transfected with varying amounts of expression vectors for TFs in the quail QT6 fibroblast cell line (Figure 6 ). Neither Sall4 nor Sox8 alone activated the core octamer (Figure 6c) . However, together they activated it in a concentration-dependent fashion and this activation was abolished by mutations 3 or 6. Sall3 did not replace Sall4 in the activation of the core enhancer (Figure 6d) . Furthermore, neither Sox2 (SoxB1) nor Sox11 (SoxC) failed to activate the core octamer with Sall4. The second SoxE protein, Sox9, also activated the core octamer in cooperation with Sall4 and even activated it in the absence of Sall4 at high levels (Figure 6c ), presumably functioning as a Sox9 dimer: this attribute of Sox9 has been previously identified (Bridgewater et al., 2003; Sock et al., 2003) , as the overlap between the ACAGAG sequence and the Sall4 binding sequence CAGAGC resembles the known Sox9 dimer binding motifs (Bridgewater et al., 2003; Kamachi & Kondoh, 2013) . However, binding of the Sox9 dimer to the Otic1 sequence is presumably optional, in the presence of Sall4, Sox9 activated the enhancer in a way that was dependent on the level of Sall4 (Figure 6c ).
Taken together with the TF expression patterns, these findings indicate that the Otic1 enhancer is activated by the combined action of Sall4 and SoxE TFs.
| Otic1 activity in otic placode tissue developed from mouse embryonic stem cells
As shown in Figure 7a , the Otic1 enhancer sequence is only conserved in birds and the turtle branch of reptiles. However, if the transcriptional regulation of otic placode development is more widely conserved across species, it will also be possible to activate the Otic1 enhancer in an otic placode-specific fashion in non-avian embryonic tissues. A classic example of such an occurrence is the chicken δ-crystallin gene, which is regulated correctly in mouse lens tissues despite mice lacking this gene (Kondoh, Yasuda, & Okada, 1983; Kondoh et al., 1987; Takahashi et al., 1988) .
We derived otic placode tissues from mouse ESCs adopting the protocol developed by Oshima et al. (2010) . After 5 days of embryoid body development from ESCs in the presence of insulin-like growth factor (IGF) and under inhibition of Wnt and Nodal signaling, the cell masses were further cultured for 3 days under adherent culture conditions in the presence of Fgf factor. This led to Pax2-positive cell patches representing the otic placode tissue developing in a way that was dependent on the addition of Fgf factor in the second phase of the culture (Figure 7c ). (Murko & Bronner, 2017) and ovalbumin intron 1 sequence (Sugahara et al., 2018) . ChIP-qPCR with each of the antibodies and normal rabbit IgG was performed using four biological replicates for each genomic site. A one-way ANOVA with a Tukey-Kramer post hoc test was used to evaluate statistical significance of the differences for any pair of data sets, which gave following results: (a) Anti-Sall4; F(2, 9) = 203. 
To monitor Otic1 enhancer activation, the Otic1 enhancer sequence was placed upstream of the tTA-VP16 activation domain (AD) expression cassette, which will activate the co-introduced EGFP gene that is expressed upon tTA-VP16AD binding to tetracycline responsive element (TRE; Figure 7b ). These expression vectors harboring Tol2 integration sequences were co-introduced into ESCs with the Tol2 transposase vector. The transfectant ESCs were cultured for otic placode development as described above, and stained for Pax2 and Otic1-dependent EGFP. As shown in Figure 7c , EGFP expression was strongly correlated with Pax2 expression, indicating that the Otic1 enhancer was activated in the otic placode of mouse tissues.
| Activity of the 68-bp minimal activation sequence of Otic1 in zebrafish embryos
To further confirm the phylogenetic conservation of Sall4 and SoxE-dependent mechanism to activate genes in the otic placode,
we injected the nuclear Venus-encoding transgene carrying the tetramer of the 68-bp minimal activation sequence of Otic1 into zebrafish fertilized eggs to produce primary transgenic embryos.
After 24 
| D ISCUSS I ON
This study aimed to clarify the basic transcriptional regulators that specify the otic placode and its tissue derivatives by focusing on the Sox3-associated enhancer Otic1. Otic1 is unique among Sox2-and Sox3-associated enhancers because of its limited specificity to and its activity across the entire tissue area of the otic placode (Nishimura et al., 2012; Okamoto et al., 2015; Uchikawa et al., 2003) .
The Otic1 enhancer sequence that was included in the 5-kb D3 sequence determined in our previous study (Nishimura et al., 2012) was narrowed down to a 181-bp region, and further dissected into a 68-bp minimal activating sequence and its 25-bp core sequence.
The core sequence comprised Sall4 and SoxE binding sites that were separated by a spacer sequence. A transactivation assay using a quail fibroblast cell line indicated that a combination of Sall4 plus Sox8 or Sox9 activated the core enhancer. However, the replacement of Sall4 with Sall3 was ineffective, and neither Sox2 (SoxB1) nor Sox11
(SoxC) could replace SoxE in the core enhancer activation. A comparison of the expression pattern of genes in chicken embryos around developmental stage 11 further indicated that SoxE TFs, Sox8, Sox9, and possibly Sox10, are the major players that cooperate with Sall4 to activate the Otic1 enhancer in embryos.
The high specificity of SoxE TFs as the counterpart to activate the minimal sequence of Otic1 makes a contrast to the case of Sox2 NOP1 enhancer core that also depends on Sall4-SoxE combination for its activation, but is also activated by Sall4-SoxB1 combination (Sugahara et al., 2018) . This difference may be accounted for by the difference in the spacing between the binding sites of the two TFs;
ACAGAGCTTCTTTTGTA for Otic1 vs ATAGAGCCTTTGTT for NOP1, where single and double underlines indicate the Sall4 and Sox TF binding sequences, respectively. In the case of Sox2/Pou5f1-dependent enhancers also, the spacing between the TF binding sequences is critical to whether other Pou factors can replace Pou5f1 in the enhancer activation (Kamachi & Kondoh, 2013; ). An influence of neighboring sequences is also possible.
The enhancer activity that is generated by Sall4 and Sox8/Sox9 binding to the core sequence is very weak and detectable only by the octamerized sequence. However, with the aid of adjoining booster sequences, the enhancer activity generated by the core sequence was increased remarkably. This boosted enhancer activity was detected in both the otic placode and the cephalic neural crest.
However, the inclusion of the 3′-positioned CAGGTG sequence, which serves as a binding site for the repressor TFs δEF1/Zeb1, Sip1/Zeb2, and Snail2/Slug, restricts the enhancer activity to the otic placode.
Based on these observations, the following model was developed. Since Sall4 expression is widespread, it is the expression domain of Sox8, which is strong in both the cephalic neural crest and otic placode that primarily determines the location of the coredependent enhancer activity. Then, the repressive effect of the Zeb family TFs δEF1 and Sip1, as well as Snail2, which are expressed in the cephalic neural crest of chicken embryos (Del Barrio & Nieto, 2004; Rogers et al., 2013; Yasumi et al., 2016) , restricts this activity to the otic placode.
The involvement of Sox8 in otic placode development has been previously indicated by the observation that the major enhancer of
The activity of the 68-bp minimal activating sequence of Otic1 in the otic vesicle and cephalic tissues in transient transgenic zebrafish embryos.
Tetramer of the 68-bp sequence was used to activate the tk-nlsVenus transgene (Okuda et al., 2010) . Two examples of transient transgenic embryos at 24 hr are shown. Ct, cephalic tissues; ov, otic vesicle. The bar indicates 200 μm Sox10, which is expressed in both otic vesicle and neural crest populations, is activated in a Sox8-dependent fashion specifically in the otic vesicle (Betancur et al., 2011) . Although that study reported the involvement of Sox8, Pea3, and Myb in the activation of the Sox10 E2 enhancer in the otic placode, the enhancer sequence contains multiple copies of the Sall4 binding sequences, raising the possibility that Sall4-Sox8 cooperation may also be involved in the activation of the Sox10 enhancer.
Although Sall4 expression is widespread, several lines of evidence indicate that it plays a central role in otic placode development. Sall4 is the causal gene for Okihiro syndrome in humans, which is characterized by inner ear defects that develop as a result of hetero-insufficiency of Sall4 expression levels (Borozdin et al., 2004; Kohlhase et al., 2002) , as confirmed using a mouse model (Warren et al., 2007) . Furthermore, in chicken embryos, Sall4 downregulation impaired otic placode invagination (Barembaum & Bronner-Fraser, 2007 ).
Thus, Sall4-Sox8 cooperation appears to be a core mechanism in the activation of genes in the otic placode, but the cooperation per se also activates genes in the cephalic neural crest. In the case of Otic1, the inclusion of a single Zeb factor/Snail2 binding sequence CAGGTG was sufficient to turn off this activity in the cephalic neural crest population, which is consistent with the expression of these repressor TFs in the cephalic neural crest of chicken embryos (Del Barrio & Nieto, 2004; Rogers et al., 2013; Yasumi et al., 2016) .
A parallel investigation of the NOP1 enhancer of Sox2, which is bipotent for the nasal and otic placodes, also indicated an analogous scenario, i.e., Sall4-Sox-dependent activation, combined with Zeb/ Snail2-dependent repression (Sugahara et al., 2018) . The activation of both Otic1 and NOP1 by Sall4-Sox TF occurred in a broad range of cephalic tissues, but the enhancer activity outside the placodal tissues was inhibited by multiple repressive mechanisms.
The Otic1 sequence positioned downstream of the Sox3 gene was found only in birds and the turtle branch of reptiles (Figure 7a ).
However, when introduced into mouse ESCs, the otic placode patches that developed using the protocol reported by Oshima et al. (2010) were precisely marked by the Otic1 enhancer activity (Figure 7c ). In addition, the 68-bp minimal activating sequence of Otic1 was activated in otic vesicle and cephalic tissues in transient transgenic zebrafish embryos (Figure 8 ). These observations indicate that the mechanism that activates the enhancer in an otic placodespecific fashion is conserved in mammalian and fish embryonic cells.
This also suggests that the Otic1 enhancer could be used in isolation of a pure population of otic placode cells derived from ESCs or analogous cells, potentially representing a therapeutic application for the treatment of auditory defects in the future.
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